Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Perception of Physicians & Patients of AMD

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent
Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).

Exclusion criteria

Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1
Upper Respiratory Tract Infection in the previous four weeks
Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.
Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.
Previous enrollment in a clinical study
Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose

Treatment and study plan

Symbicort

Drug

Primary outcomes

Patient satisfaction with the adjustable maintenance dosing schedule

Time frame: Throughout the study
Physicians' satisfaction with the adjustable maintenance dosing schedule

Time frame: Throughout the study

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: REALITY

Important dates

Study start: 2006
Study completion: 2007
First posted: Dec 22, 2008
Registry last updated: Jan 24, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.